Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim

NCT01712009 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01712009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2012
Completion date
March 18, 2015
Enrollment
600 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

bone pain in stage i - iii breast cancer